Pre-made Briakinumab benchmark antibody ( Whole mAb, anti-IL12B therapeutic antibody, Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Briakinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-081-1mg	1mg	3090
GMP-Bios-ab-081-10mg	10mg	Inquiry
GMP-Bios-ab-081-100mg	100mg	Inquiry
GMP-Bios-ab-081-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Briakinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody
INN Name	Briakinumab
Target	IL12B
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Preregistration (w)
Est. Status	Discontinued
100% SI Structure	5n2k:LK:BA:PO:DC:NM:FE
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Cambridge Antibody Technology;Abbott GmbH & Co. KG
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis
Development Tech	na